55 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
activities, provided that such engagement does not interfere with Executive’s duties and responsibilities hereunder.
(c)During the Employment Period … by Executive may result in the withdrawal of the offer of engagement or the termination of Executive’s employment with the Company. Immediately upon
8-K
EX-10.3
ck2mgc9cr5
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
gbtpnbb amtj
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
fv4vwheo2p7iwi
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
w3tki41lnieg6 0q9do4
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
xi6o1wng17273qj
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
c9umz
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
6y10v97nfr4
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-10.1
7ebhq oabb
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
EX-10.01
3jxu w81d9oa
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am
8-K
EX-99.1
77l 3pjxb5950wr8l
13 Sep 21
Other Events
7:08am